argenx
Tim Van Hauwermeiren is the current CEO at argenx. Prior to joining argenx, they were a Senior Business Development Executive at Ablynx NV from July 2003 to July 2008. Tim was instrumental in the EUR 25 mio series B, EUR 40 mio series C equity financing rounds and the EUR 85 mio IPO on Euronext Brussels. Tim was also responsible for all in-licensing and major sub-contracting activities. Before joining Ablynx, they worked at Procter&Gamble from July 1995 to July 2003 where they held various management positions in R&D and Corporate New Business Development. Among their accomplishments, they conceived and developed several new-to-the-world products, winning the United Nations ICC World Business Award in 2004. In 2000, they were awarded the F&HC New Business Development Award for Outstanding Courage and Committment. In 2001, they were nominated for the John Smale Innovation award.
Tim Van Hauwermeiren has a certificate in high performance boards from IMD, an eMBA from Vlerick Business School, and a certification in innovation management from INSEAD. Tim also has a YMP from INSEAD and an MSc in bioengineering from Ghent University.
Arjen Lemmen - VP, Corporate Development & Strategy, Keith Woods - COO, and Malini Moorthy - General Counsel report to Tim Van Hauwermeiren.
This person is not in any offices
argenx
31 followers
Argenx discovers, designs and develops innovative antibody therapeutics for its own pipeline of treatments for cancer and autoimmune diseases and for its partners. Harnessing our technology and know-how, we aim to meet the needs of patients by engineer...